Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024
Nektar(NKTR) Prnewswire·2024-06-12 13:30– NKTR-0165 Demonstrates Selective Enhancement of Treg Cell Function Through Novel Agonistic Mechanism – The poster presentation is available for download at www.nektar.com/science/scientific-posters-andpresentations. Abstract 3174: "A Novel Therapeutically Active Anti-TNFR2 Agonistic Antibody Promotes Treg Proliferation and Induction of Treg Functional Markers", Miyazaki, et al. Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immuno ...